



February 9, 2023

bioMérieux, Inc.
Kyle Olney
Regulatory Affairs Specialist
595 Anglum Rd.
Hazelwood, Missouri 63042

Re: K222073

Trade/Device Name: Vitek 2 AST Gram Negative Cefazolin ($\leq 1 - \geq 32$ $\mu\text{g/mL}$)

Regulation Number: 21 CFR 866.1645

Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System

Regulatory Class: Class II

Product Code: LON

Dated: July 12, 2022

Received: July 14, 2022

Dear Kyle Olney:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR

803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Ribhi Shawar -S

Ribhi Shawar, Ph.D. (ABMM)
Branch Chief
General Bacteriology and Antimicrobial Susceptibility
Branch
Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K222073

Device Name

VITEK[®] 2 AST-Gram Negative Cefazolin ($\leq 1 - \geq 32$ $\mu\text{g/mL}$)

Indications for Use (Describe)

VITEK[®] 2 AST-Gram Negative Cefazolin is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK[®] 2 and VITEK[®] 2 Compact Systems as a laboratory aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK[®] 2 AST-Gram Negative Cefazolin is a quantitative test. Cefazolin has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.

Active *in vitro* and in clinical infections:

Escherichia coli

Proteus mirabilis

The VITEK[®] 2 Gram-Negative Susceptibility Card is intended for use with the VITEK[®] 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



**VITEK® 2 AST-GN Cefazolin
Traditional 510(k) Submission**

510(k) SUMMARY

VITEK® 2 AST-Gram Negative Cefazolin ($\leq 1 - \geq 32$ $\mu\text{g/mL}$)

510(k) Submission Information:

Submitter's Name: bioMérieux, Inc.
Address: 595 Anglum Road
Hazelwood, MO 63042
Contact Person: Kyle Olney
Regulatory Affairs Specialist
Phone Number: 314 -805-8642
Fax Number: 314-731-8689
Date of Preparation: June 24, 2022

B. Device Name:

Formal/Trade Name: VITEK® 2 AST-Gram Negative Cefazolin ($\leq 1 - \geq 32$ $\mu\text{g/mL}$)
Classification Name: 21 CFR 866.1645
Fully Automated Short-Term Incubation Cycle
Antimicrobial Susceptibility System
Product Code: LON

Common Name: VITEK® 2 AST-GN Ciprofloxacin ($\leq 1 - \geq 32$ $\mu\text{g/mL}$)

C. Predicate Device: VITEK® 2 AST-GN Omadacycline ($\leq 0.25 - \geq 16$ $\mu\text{g/mL}$)
(K213931)

D. Device Description:

The principle of the VITEK® 2 AST cards is based on the microdilution minimum inhibitory concentration (MIC) technique reported by MacLowry and Marsh⁽¹⁾ and Gerlach⁽²⁾. The VITEK® 2 AST card is essentially a miniaturized, abbreviated and automated version of the doubling dilution technique⁽³⁾.



**VITEK® 2 AST-GN Cefazolin
Traditional 510(k) Submission**

Each VITEK® 2 AST card contains 64 wells. A control well which only contains microbiological culture media is resident on all cards. The remaining wells contain premeasured portions of a specific antibiotic combined with culture media. The bacterial or yeast isolate to be tested is diluted to a standardized concentration with 0.45 – 0.5% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 System automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling, sealing and loading operation. The VITEK® 2 Systems monitor the growth of each well in the card over a defined period of time. At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card.

VITEK® 2 AST-GN Cefazolin ($\leq 1 - \geq 32$ µg/mL) has the following concentrations in the card: 1, 2, and 8 µg/mL (equivalent standard method concentration by efficacy in µg/mL).

E. Substantial Equivalence Information:

The similarities and differences of the VITEK® 2 AST-GN Cefazolin ($\leq 1 - \geq 32$ µg/mL) when compared to the predicate device, VITEK® 2 AST-GN Omadacycline ($\leq 0.25 - \geq 16$ µg/mL), are described in the [Table 1](#) below.

Table 1: Substantial Equivalence

Item	Device: VITEK® 2 AST-Gram Negative Cefazolin ($\leq 1 - \geq 32$ µg/mL)	Predicate: VITEK® 2 AST-Gram Negative Omadacycline ($\leq 0.25 - \geq 16$ µg/mL) (K213931)
Similarities		
Intended Use	<p>VITEK® 2 AST-Gram Negative Cefazolin is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of <i>in vitro</i> susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Negative Cefazolin is a quantitative test.</p> <p>The VITEK® 2 Gram-Negative Susceptibility Card is intended for use with the VITEK® 2 Systems in clinical laboratories as an <i>in vitro</i> test to determine the susceptibility of</p>	<p>VITEK® 2 AST-Gram Negative Omadacycline is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of <i>in vitro</i> susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Negative Omadacycline is a quantitative test.</p> <p>The VITEK® 2 Gram-Negative Susceptibility Card is intended for use with the VITEK® 2 Systems in clinical laboratories as an <i>in vitro</i></p>



**VITEK® 2 AST-GN Cefazolin
Traditional 510(k) Submission**

	clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed.	test to determine the susceptibility of clinically significant aerobic Gram negative bacilli to antimicrobial agents when used as instructed.
Test Methodology	Automated quantitative antimicrobial susceptibility test for use with the VITEK® 2 and VITEK® 2 Compact Systems to determine the <i>in vitro</i> susceptibility of microorganisms	Same
Inoculum	Saline suspension of organism	Same
Test Card	Gram Negative (AST-GN) Susceptibility Card	Same
Instrument	VITEK® 2 and VITEK® 2 Compact Systems	Same
Type of Test	VITEK® 2 AST-Gram Negative Cefazolin is a quantitative test.	Same
Differences		
Antimicrobial Agent	Cefazolin	Omadacycline
Concentrations	1, 2, 8	0.5, 2, 8, 16
Indications for use	<p>Cefazolin has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.</p> <p><u>Active <i>in vitro</i> and in clinical infections:</u> <i>Escherichia coli</i> <i>Proteus mirabilis</i></p>	<p>Omadacycline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.</p> <p><u>Active <i>in vitro</i> and in clinical infections:</u> For ABSSSI: <i>Enterobacter cloacae</i> <i>Klebsiella pneumoniae</i> For CABP: <i>Klebsiella pneumoniae</i></p>

F. Intended Use:

VITEK® 2 AST-Gram Negative Cefazolin is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of *in vitro* susceptibility to antimicrobial agents. VITEK® 2 AST-Gram Negative Cefazolin is a quantitative test. Cefazolin has been shown to



**VITEK® 2 AST-GN Cefazolin
Traditional 510(k) Submission**

be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.

Active in vitro and in clinical infections:

Gram-Negative Bacteria:

Escherichia coli
Proteus mirabilis

The VITEK® 2 Gram-Negative Susceptibility Card is intended for use with the VITEK® 2 Systems in clinical laboratories as an *in vitro* test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed.

G. Performance Overview and Conclusion:

VITEK® 2 AST-GN Cefazolin demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA (Issued August 28, 2009).

The Premarket Notification (510[k]) presents data in support of VITEK® 2 AST-GN Cefazolin. An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to confirm the acceptability of VITEK® 2 AST-GN Cefazolin by comparing its performance with the CLSI broth microdilution reference method incubated at 16-24 hrs. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms.

The VITEK® 2 AST-GN Cefazolin demonstrated acceptable performance as presented in **Table 2** below:

Table 2: VITEK® 2 AST-GN Cefazolin Performance

Antimicrobial	Antimicrobial Code	Antibiotic Version	Bp ¹	Comment ²	Essential Agreement				Category Agreement				% Reproducibility
					% Error				% Error				
					% EA	VME	ME	mE	% CA	VME	ME	mE	
Cefazolin	CZ	cz05n	CLSI (FDA)	#, E <i>Enterobacteriaceae</i>	97.4	N/A	N/A	N/A	83.6	0.8	1.3	15.6	100

Reproducibility and Quality Control demonstrated acceptable results.



**VITEK® 2 AST-GN Cefazolin
Traditional 510(k) Submission**

H. References:

1. MacLowry, J.D. and Marsh, H.H., Semi-automatic Microtechnique for Serial Dilution Antibiotic Sensitivity Testing in the Clinical laboratory, *Journal of Laboratory Clinical Medicine*, 72:685-687, 1968.
2. Gerlach, E.H., Microdilution 1: A Comparative Study, p. 63-76. *Current Techniques for Antibiotic Susceptibility Testing*. A. Balows (ed.), Charles C. Thomas, Springfield, IL, 1974.
3. Barry, A.L., *The Antimicrobial Susceptibility Test, Principles and Practices*, Lea and Febiger, Philadelphia, PA, 1976.